Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream
Status:
Completed
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
This study investigates the efficacy of photodynamic therapy (PDT) in the treatment of
lentigo maligna (LM). Hyperspectral imaging system (HIS) will be used to determine the
margins of LM and to rule out possible invasion. Participants will receive photodynamic
therapy three times consecutively with intervals of two weeks using 5-aminolevulinic acid
nanoemulsion (BF-200 ALA, Ameluz®) as a light sensitizing cream. Four weeks after last
photodynamic therapy the lentigo maligna lesion will be excised surgically from the skin.
Result of the treatment is assessed with histopathological examination and
immunohistochemical staining of removed tissue specimen.
Phase:
Phase 4
Details
Lead Sponsor:
Joint Authority for Päijät-Häme Social and Health Care
Collaborators:
Huslab, Finland Tampere University University of Tampere